Adam Hauben
@ahauben4Oncology/ Philadelphia Sports
Similar User
@DCLedford5
@fizzylizzy07
@JoanneXiu
Caris welcomes Dr. George W. Sledge, Jr. (@GeorgeSledge51) as Chief Medical Officer. Dr. Sledge brings over 30 years of oncology research and practice experience to the company and will oversee Caris’ Medical Affairs group. Learn more: carislifesciences.com/about/news-and…
Caris is sponsoring a symposium at this year’s International Gynecologic Cancer Society (@IGCSociety) annual meeting focused on exploring the importance of comprehensive #molecularprofiling in gynecologic cancer. Join our expert panel October 1st. #IGCS2022
G rind R elentless I ntegrity N now D ependable
If it’s a target, it’s a pan-cancer target
Appreciate the Division Chief of Gynecologic Cancer @StephensonCC @OUHealth ⬇️ @DebbieRic23 stopping by @carisls @ASCO @ahauben4 🎯 🧬 #WinTheDay
Such an honor to have @AmerCancerCEO as our @carisls POA keynote speaker to discuss the vision of the American Cancer Society to improve on patient care, precision medicine, and mitigate disparities. @ASCO #ASCO22
Thank you @carisls for bringing attention to the importance of molecular testing. It is such an honor to care for brave women like Diane. #ovariancancer
Diane was shocked to learn her ovarian cancer did not respond to chemotherapy. She felt overwhelming despair until her oncologist, @topherdarus, ordered a Caris test. Hear how molecular profiling revealed alternative options for Diane’s cancer treatment. ow.ly/Z9iU50HMS3Q
Excellent review of the role of NGS in clinical care
The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff @sloan_kettering who have made this initiative possible. A few thoughts on what we have learned.
Nationally recognized @DukeCancer and @CedarsSinai, become the 32nd and 33rd member of Caris’ collaborative network focused on expanding the application of precision medicine in cancer treatment. carislifesciences.com/about/news/
The last FDA approval of 2019 was also the first approved BRCA targeted therapy in pancreatic cancer, marking GI oncology another exciting field that had many advances in 2019. Which field did you find most exciting in 2019 in terms of FDA approvals? #oncoalert #FDANews #oncology
As we look forward to advances in the new year, we can also reflect on relevant FDA approvals from 2019. What field do you think had the most impactful additions to its armamentarium? Choose from the options below or Tweet us with other picks! #bcsm #lcsm #hematology #oncology
"We do more cancer-specific, treatment-geared IHC work than any other laboratory. It's only at that volume that you can see the broad heterogeneity between cancer cases and know what's important." - Dr. David Spetzler, #CarisLS President & Chief Scientific Officer.
The average survival of patients with mCRC hovers around 3 years, but by understanding where the tumor originated and the increasing array of molecular markers, clinicians have a better chance of optimizing outcomes #crcsm onclive.com/web-exclusives…
An informative synopsis from @urotoday of Dr. @Robert_Uzzo's presentation at #ASCO19 where he discusses the role of cytoreductive nephrectomy in the post-CARMENA era. bit.ly/2ER8rcf @FCUroOnc
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM a new standard of care for patients with metastatic pancreatic cancer & germline BRCA mutations; all such patients must be tested nejm.org/doi/full/10.10…
BREAKING: The #FDA approved frontline #pembrolizumab as monotherapy or in combination with chemotherapy for metastatic or unresectable head and neck squamous cell carcinoma... targetedonc.com/news/upfront-p…
Vaccine Opponents Haven't Looked at the Evidence @DrMaurieMarkman @CancerCenter onclive.com/publications/O…
Dr.Uzzo @FoxChaseCancer on nephrectomy in setting of #kidneycancer mets: Met RCC is an ecosystem, not linear model of progression. Need to work towards a biologic basis of pt selection. For now CNx should be done "a whole lot less than always, marginally more than never" #ASCO19
POLO study- Improved PFS with olaparib in patients with BRCA mutation compared to placebo after platinum based therapy. With over two years duration of response. Excited to offer this to my patients. #ASCO19 #PancreaticCancer.
Coauthor Joanne Xiu, Ph.D with the #CarisPOA poster on SWI/SNF gene mutations and their effect on cancer progression. The research was led by Dr. Ryuma Tokunaga from @KeckMedUSC, an #ASCO19 Merit Award winner from @ConquerCancerFd
United States Trends
- 1. South Korea 806 B posts
- 2. #GivingTuesday 54,1 B posts
- 3. Africa 221 B posts
- 4. North Carolina 111 B posts
- 5. #tomatojay 1.084 posts
- 6. #TalentWon 35,3 B posts
- 7. Snow Mexicans 3.470 posts
- 8. #USWNT N/A
- 9. #alieninvasion 8.932 posts
- 10. Yoon 392 B posts
- 11. Mayor Adams 29,8 B posts
- 12. Neuer 12,2 B posts
- 13. Lamine 74 B posts
- 14. Daniel Penny 147 B posts
- 15. Lynn Williams N/A
- 16. Happy Birthday Tiff N/A
- 17. Eric Adams 29,6 B posts
- 18. Manfred 9.198 posts
- 19. Martial Law 951 B posts
- 20. Ferran 32,9 B posts
Something went wrong.
Something went wrong.